Compare GH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | TMDX |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 3.9B |
| IPO Year | 2018 | 2019 |
| Metric | GH | TMDX |
|---|---|---|
| Price | $101.88 | $136.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 10 |
| Target Price | $79.19 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 2.4M | 835.5K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | N/A | ★ 2.54 |
| Revenue | ★ $902,569,000.00 | $566,354,000.00 |
| Revenue This Year | $34.72 | $38.84 |
| Revenue Next Year | $26.46 | $20.43 |
| P/E Ratio | ★ N/A | $53.83 |
| Revenue Growth | 30.38 | ★ 41.20 |
| 52 Week Low | $29.91 | $55.00 |
| 52 Week High | $112.43 | $156.00 |
| Indicator | GH | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 54.31 |
| Support Level | $103.36 | $133.50 |
| Resistance Level | $109.59 | $156.00 |
| Average True Range (ATR) | 5.54 | 8.50 |
| MACD | -1.11 | 0.41 |
| Stochastic Oscillator | 42.83 | 55.98 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.